IL22 and hyperlipidemia: To address these gaps, we comprehensively profiled circulating ILC subsets and plasma IL-22 in hyperlipidemia patients and healthy controls, evaluated the lipid-lowering efficacy of WMT in a prospective cohort without lipid-lowering medications, and performed microbiome and metabolomic analyses to characterize treatment-associated changes.